Contrast Injector Market – Key players and global forecast 2021
According to research report the contrast injectors market is projected to reach USD 636.1 Million by 2021
(EMAILWIRE.COM, May 01, 2019 ) According to research report the contrast injectors market is projected to reach USD 636.1 Million by 2021 from USD 445.5 Million in 2016, growing at a CAGR of 7.4% during the forecast period.
A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=96046959
Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients. The company’s notable revenue is from the European region followed by North America and RoW. The company maintains a direct sales force to reach out to its customers. It succeeded in creating a strong foothold in the market, owing to its diversified product portfolio, wide geographic reach, and focus on acquisitions and product launch.
Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96046959
The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents. The company continuously strives to strengthen its market position in various geographies by focusing on expansion and acquisitions for its contrast media injector products. The company acquired Medrad Inc., (U.S.) in 2011; the acquisition enabled Bayer AG to leverage its injector technology. In March 2014, the company invested around USD 132.9 million (EUR 100 million) to increase the production capacity of its plant in Beijing, China. This establishment enabled the company to meet the growing demand for its products by customers in China.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com
A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=96046959
Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients. The company’s notable revenue is from the European region followed by North America and RoW. The company maintains a direct sales force to reach out to its customers. It succeeded in creating a strong foothold in the market, owing to its diversified product portfolio, wide geographic reach, and focus on acquisitions and product launch.
Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96046959
The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents. The company continuously strives to strengthen its market position in various geographies by focusing on expansion and acquisitions for its contrast media injector products. The company acquired Medrad Inc., (U.S.) in 2011; the acquisition enabled Bayer AG to leverage its injector technology. In March 2014, the company invested around USD 132.9 million (EUR 100 million) to increase the production capacity of its plant in Beijing, China. This establishment enabled the company to meet the growing demand for its products by customers in China.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com
Contact Information:
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results